MADRID, Feb 1 (Reuters) - Shares in PharmaMar rose more than 7% in early trade on Monday after the Spanish pharmaceutical firm and its U.S. partner Jazz Pharmaceuticals reported positive results from a trial of their Zepzelca drug to treat lung cancer.
Results from the early-stage trial on 21 patients showed a combination of Zepzelca with bowel-cancer medication irinotecan proved an effective treatment for small-cell lung cancer, PharmaMar said in a media release.
The combination was particularly effective in patients for whom an initial treatment had failed to cure the disease, PharmaMar said.
Early results showed the combination had a manageable safety profile, with no deaths from toxicity stemming from the treatment, the company said.
Complete data will be presented at a future congress, PharmaMar said, adding that it planned to include 47 patients in the current cohort.
At 1042 GMT shares in PharmaMar were trading 7% higher at 112.40 euros ($135.69), leading gainers on Spain’s blue-chip IBEX-35 index.
$1 = 0.8284 euros Reporting by Tomás Cobos; writing by Nathan Allen; editing by Inti Landauro and Jason Neely